Diagnosis and Management of Lipid Transfer Protein Allergy—A BSACI Clinical Practice Statement

Keywords Allergy, lipid transfer protein, food allergy, pollen food syndrome, diagnosis, management, diet, adrenaline, co-factors, clinical research     Summary In this episode of the Clinical and Experimental Allergy podcast, hosts Mo Shamji and Robert Boyle engage with Dr. Isabel Skypala, a consultant allergy dietician, to discuss the increasing recognition of lipid transfer protein (LTP) allergy in the UK. Dr. Skypala shares insights into the challenges of diagnosing LTP allergy, particularly due to its overlap with pollen food syndrome, and emphasizes the importance of a thorough clinical history. The conversation also covers management strategies for patients with LTP allergy, including the role of co-factors, the creation of safe diets, and considerations for the use of adrenaline auto-injectors. Dr. Skypala highlights the need for individualized approaches in allergy management, ensuring that patients can maintain a balanced diet while avoiding triggers.   Takeaways LTP allergy is increasingly recognized in the UK. Diagnosis requires careful clinical history taking. Symptoms of LTP allergy can vary significantly. Cofactors like exercise and alcohol can trigger reactions. Individualized dietary plans are essential for patients. Food challenges can help identify safe foods. Different varieties of fruits may be tolerated differently. Adrenaline auto-injectors may be necessary for high-risk patients. Management strategies must consider lifestyle factors. Collaboration among clinicians is vital for effective allergy management. Chapters   00:00 Introduction to the speakers 01:17 Understanding Lipid Transfer Protein Allergy 02:54 Challenges in Diagnosing LTP Allergy 04:22 Management Strategies for LTP Allergy with co-factors 05:32 Dietary Considerations and Food Challenges 07:21 Adrenaline Auto-Injectors and Risk Assessment 08:41 Closing the podcast

Om Podcasten

Summary This conversation highlights the significant contributions of the Clinical and Experimental Allergy (CEA) journal to the field of allergy research and clinical practice. The hosts and Editors-In-Chief discuss the journal’s achievements, including advancements in allergy diagnosis, innovative treatments, and a focus on patient-centric research. They also outline future directions for the journal, emphasising collaboration and accessibility in allergy research. Takeaways - CEA is a leading publication in allergy and immunology. - The journal publishes groundbreaking research on allergy mechanisms. - Innovative diagnostic methods are a focus of CEA’s contributions. - Promising new treatments, including biologics, are showcased. - Food allergy research informs better management practices. - Environmental factors influencing allergies are examined. - Patient-reported outcomes are prioritised in research. - The journal’s Impact Factor has reached a record high. - Future plans include enhancing author support and engagement. - Collaboration with patient organisations is a key focus for CEA.